Premenstrual Syndromes : PMS and PMDD - Rutuja :: The site ...

168 THE PREMENSTRUAL SYNDROMES
28. Rapkin AJ, Edelmuth E, Chang LC et al. Whole-blood serotonin
in premenstrual syndrome. Obstet Gynecol 1987; 70(4):533–7.
29. Rapkin AJ, Buckman TD, Sutphin MS, Chang LC, Reading AE.
Platelet monoamine oxidase B activity in women with premenstrual
syndrome. Am J Obstet Gynecol 1988; 159(6):1536–40.
30. Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S.
Imipramine receptor binding and serotonin uptake in platelets of
women with premenstrual changes. Gynecol Obstet Invest 1991;
31(3):146–52.
31. Parry BL. The role of central serotonergic dysfunction in the
aetiology of premenstrual dysphoric disorder: therapeutic implications.
CNS Drugs 2001; 15(4):277–85.
32. Eriksson O, Wall A, Marteinsdottir I et al. Mood changes
correlate to changes in brain serotonin precursor trapping in
women with premenstrual dysphoria. Psychiatry Res 2006;
146(2):107–16.
33. Ho HP, Olsson M, Westberg L, Melke J, Eriksson E. The serotonin
reuptake inhibitor fluoxetine reduces sex steroid-related
aggression in female rats: an animal model of premenstrual irritability?
Neuropsychopharmacology 2001; 24(5):502–10.
34. Eriksson E, Humble M. Serotonin in psychiatric pathophysiology.
A review of data from experimental and clinical research. In:
Gershon S, Pohl R, eds. Progress in Basic Clinical Pharmacology.
Basel: Karger; 1990:66–119.
35. Rubinow DR, Schmidt PJ, Roca CA. Estrogen–serotonin interactions:
implications for affective regulation. Biol Psychiatry
1998; 44(9):839–50.
36. Joffe H, Cohen LS. Estrogen, serotonin, and mood disturbance:
where is the therapeutic bridge? Biol Psychiatry 1998; 44(9):
798–811.
37. Eriksson E, Alling C, Andersch B, Andersson K, Berggren U.
Cerebrospinal fluid levels of monoamine metabolites. A preliminary
study of their relation to menstrual cycle phase, sex
steroids, and pituitary hormones in healthy women and in
women with premenstrual syndrome. Neuropsychopharmacology
1994; 11(3):201–13.
38. Leibenluft E, Fiero PL, Rubinow DR. Effects of the menstrual
cycle on dependent variables in mood disorder research. Arch
Gen Psychiatry 1994; 51(10):761–81.
39. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C,
Lu ZN. Ovarian steroids and serotonin neural function. Mol
Neurobiol 1998; 18(2):87–123.
40. FitzGerald M, Malone KM, Li S et al. Blunted serotonin
response to fenfluramine challenge in premenstrual dysphoric
disorder. Am J Psychiatry 1997; 154(4):556–8.
41. Rapkin AJ, Reading AE, Woo S, Goldman LM. Tryptophan and
neutral amino acids in premenstrual syndrome. Am J Obstet
Gynecol 1991; 165(6 Pt 1):1830–3.
42. Rapkin AJ, Morgan M, Goldman L et al. Progesterone metabolite
allopregnanolone in women with premenstrual syndrome.
Obstet Gynecol 1997; 90(5):709–14.
43. Dimmock PW, Wyatt KM, Jones PW, O’Brien PM. Efficacy of
selective serotonin-reuptake inhibitors in premenstrual syndrome:
a systematic review. Lancet 2000; 356(9236):1131–6.
44. van den Berg H, Louwerse ES, Bruinse HW, Thissen JT, Schrijver J.
Vitamin B 6 status of women suffering from premenstrual syndrome.
Hum Nutr Clin Nutr 1986; 40(6):441–50.
45. Stromberg J, Haage D, Taube M, Backstrom T, Lundgren P.
Neurosteroid modulation of allopregnanolone and GABA effect
on the GABA-A receptor. Neuroscience 2006; 143(1):78–81.
46. Wong CG, Bottiglieri T, Snead OC 3rd. GABA, gammahydroxybutyric
acid, and neurological disease. Ann Neurol
2003; 54(Suppl 6):S3–12.
47. Epperson CN, Haga K, Mason GF et al. Cortical gammaaminobutyric
acid levels across the menstrual cycle in healthy
women and those with premenstrual dysphoric disorder: a proton
magnetic resonance spectroscopy study. Arch Gen Psychiatry
2002; 59(9):851–8.
48. Halbreich U, Petty F, Yonkers K et al. Low plasma gammaaminobutyric
acid levels during the late luteal phase of women
with premenstrual dysphoric disorder. Am J Psychiatry 1996;
153(5):718–20.
49. Gulinello M, Gong QH, Smith SS. Progesterone withdrawal
increases the anxiolytic actions of gaboxadol: role of
alpha4betadelta GABA(A) receptors. Neuroreport 2003; 14(1):
43–6.
50. Lovick TA. Plasticity of GABAA receptor subunit expression
during the oestrous cycle of the rat: implications for premenstrual
syndrome in women. Exp Physiol 2006; 91(4):655–60.
51. Maguire JL, Stell BM, Rafizadeh M, Mody I. Ovarian cyclelinked
changes in GABA(A) receptors mediating tonic inhibition
alter seizure susceptibility and anxiety. Nat Neurosci 2005;
8(6):797–804.
52. Romeo E, Strohle A, Spalletta G et al. Effects of antidepressant
treatment on neuroactive steroids in major depression. Am J
Psychiatry 1998; 155(7):910–13.
53. Rapkin AJ, Shoupe D, Reading A et al. Decreased central opioid
activity in premenstrual syndrome: luteinizing hormone response
to naloxone. J Soc Gynecol Investig 1996; 3(2):93–8.
54. Chuong CJ, Coulam CB, Kao PC, Bergstralh EJ, Go VL.
Neuropeptide levels in premenstrual syndrome. Fertil Steril
1985; 44(6):760–5.
55. Chuong CJ, Hsi BP, Gibbons WE. Periovulatory beta-endorphin
levels in premenstrual syndrome. Obstet Gynecol 1994; 83(5 Pt
1):755–60.
56. Giannini AJ, Melemis SM, Martin DM, Folts DJ. Symptoms of
premenstrual syndrome as a function of beta-endorphin: two
subtypes. Prog Neuropsychopharmacol Biol Psychiatry 1994;
18(2):321–7.
57. Giannini AJ, Martin DM, Turner CE. Beta-endorphin decline in
late luteal phase dysphoric disorder. Int J Psychiatry Med 1990;
20(3):279–84.
58. Giannini AJ, Price WA, Loiselle RH. Beta-endorphin withdrawal:
a possible cause of premenstrual tension syndrome. Int
J Psychophysiol 1984; 1(4):341–3.
59. Marcusson JO, Ross SB. Binding of some antidepressants to
the 5-hydroxytryptamine transporter in brain and platelets.
Psychopharmacology (Berl) 1990; 102(2):145–55.
60. Lesch KP, Wolozin BL, Murphy DL, Reiderer P. Primary structure
of the human platelet serotonin uptake site: identity with the
brain serotonin transporter. J Neurochem 1993; 60(6): 2319–22.
61. Lesch KP, Wolozin BL, Estler HC, Murphy DL, Riederer P.
Isolation of a cDNA encoding the human brain serotonin transporter.
J Neural Transm Gen Sect 1993; 91(1):67–72.
62. Milford EL, Carpenter CB. Immunogenetics of Disease: Genetic
Polymorphism. Dale DC, Federman DD, eds. http://www.
medscape.com/viewarticle/534976 6. 2000. WebMD Inc.
63. Winter PC, Hickey GI, Fletcher HL. Instant Notes in Genetics.
2nd edn. Oxford: BIOS Scientific Publishers; 2000.
64. Walther DJ, Peter JU, Bashammakh S et al. Synthesis of serotonin
by a second tryptophan hydroxylase isoform. Science
2003; 299(5603):76.
65. Paoloni-Giacobino A, Mouthon D, Lambercy C et al. Identification
and analysis of new sequence variants in the human
tryptophan hydroxylase (TpH) gene. Mol Psychiatry 2000;
5(1):49–55.
66. Teerawatanasuk N, Carr LG. CBF/NF-Y activates transcription
of the human tryptophan hydroxylase gene through an inverted
CCAAT box. Brain Res Mol Brain Res 1998; 55(1):61–70.
67. Rotondo A, Schuebel K, Bergen A et al. Identification of four
variants in the tryptophan hydroxylase promoter and association
to behavior. Mol Psychiatry 1999; 4(4):360–8.